Back

Antihypertensive drugs in experimental NAFLD as the first step to the establishment of criteria for choosing appropriate treatment of hypertension in NAFLD carriers

2 September 2019 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 5 - Heart values Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Mario Claudio Soares Sturzeneker

Ponta Grossa State University, Ponta Grossa (Brazil)

11 More presentations in this session

Presentation thumbnail
Professor Y. Yang (Luzhou, CN)
Presentation thumbnail
Doctor M. Keck (Paris, FR)
Abstract
Presentation thumbnail
Professor E. Malev (Saint Petersburg, RU)
Abstract Slides
Presentation thumbnail
Doctor A. Kostina (Saint Petersburg, RU)
Abstract Slides
Presentation thumbnail
Doctor D. Arangalage (Lausanne, CH)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 5 - Heart values

The Event

Event poster

ESC Congress 2019

2 September 2019 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Elucidation of the mechanistic links connecting non-alcoholic fatty liver disease and heart failure with preserved ejection fraction in mice
thumbnail
Congress Presentation
Male patients with first diagnosed and never treated essential hypertension accompanied by organ damage are at high risk for non-alcoholic fatty liver disease indicated by Hepatic steatosis index
thumbnail
Congress Presentation
Effects of sodium-glucose contrasporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on vascular function and liver steatosis in diabetes

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources